Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Initiation	Cogent Biosciences initiated with an Overweight at Piper Sandler » 04:51 12/23/20 12/23 04:51 12/23/20 04:51 COGT Cogent Biosciences $12.19 / -0.19 (-1.53%) , BPMC Blueprint Medicines $123.72 / +2.23 (+1.84%) Piper Sandler analyst… Piper Sandler analyst Christopher Raymond initiated coverage of Cogent Biosciences (COGT) with an Overweight rating and $22 price target. The stock's risk/reward "skews meaningfully to the upside," Raymond tells investors in a research note. The company's PLX9486 can become standard of care in indolent systemic mastocytosis and may also serve as a treatment option in advanced gastrointestinal stromal tumors, says the analyst. Raymond sees a more favorable safety profile for PLX9486 compared to Blueprint Medicines' (BPMC) avapritinib and a "sizeable valuation gap." ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly COGT BPMC COGT Cogent Biosciences $12.19 / -0.19 (-1.53%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson BPMC Blueprint Medicines $123.72 / +2.23 (+1.84%) 12/17/20 Blueprint Medicines submits supplemental NDA for Ayvakit in mastocytosis 12/01/20 Blueprint Medicines announces FDA approval of Gavreto 09/25/20 Blueprint Medicines granted conditional marketing authorization for AYVAKYT 09/22/20 Blueprint Medicines announces results from trials of AYVAKIT COGT BPMC COGT Cogent Biosciences $12.19 / -0.19 (-1.53%) 12/17/20 SVB Leerink Cogent Biosciences initiated with an Outperform at SVB Leerink 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BPMC Blueprint Medicines $123.72 / +2.23 (+1.84%) 12/18/20 JMP Securities Blueprint Medicines price target raised to $152 from $118 at JMP Securities 12/14/20 BMO Capital Blueprint Medicines price target raised to $132 from $113 at BMO Capital 12/02/20 Stifel Blueprint Medicines initiated with a Hold at Stifel 11/02/20 Jefferies Jefferies cuts Blueprint to Hold with current products' potential priced in COGT BPMC COGT Cogent Biosciences $12.19 / -0.19 (-1.53%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) BPMC Blueprint Medicines $123.72 / +2.23 (+1.84%) 10/29/20 Blueprint Medicines reports Q3 EPS $11.16, consensus $7.72 07/30/20 Blueprint Medicines reports Q2 EPS ($2.28), consensus ($2.14) 02 Dec 23 Jan COGT COGT Cogent Biosciences $12.19 / -0.19 (-1.53%) 11/30/20 Fly Intel: After-Hours Movers
Initiation	Cogent Biosciences initiated with an Outperform at SVB Leerink » 08:47 12/17/20 12/17 08:47 12/17/20 08:47 COGT Cogent Biosciences $10.95 / +0.47 (+4.48%) SVB Leerink analyst… SVB Leerink analyst Christopher Liu initiated coverage of Cogent Biosciences with an Outperform rating and $20 price target. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly COGT Cogent Biosciences $10.95 / +0.47 (+4.48%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson COGT Cogent Biosciences $10.95 / +0.47 (+4.48%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg COGT Cogent Biosciences $10.95 / +0.47 (+4.48%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) 02 Dec COGT Cogent Biosciences $10.95 / +0.47 (+4.48%) 11/30/20 Fly Intel: After-Hours Movers

Over a month ago
Conference/Events	Evercore ISI to hold a virtual conference » 04:55 12/03/20 12/03 04:55 12/03/20 04:55 CMPS Compass Pathways $47.94 / +3.21 (+7.18%) , INSM Insmed $39.74 / +0.71 (+1.82%) , ALXN Alexion $122.70 / +0.55 (+0.45%) , ENTA Enanta $42.11 / +1.06 (+2.58%) , NKTX Nkarta $33.99 / -0.02 (-0.06%) , HRC Hill-Rom $96.12 / -0.16 (-0.17%) , DRNA Dicerna $24.45 / -0.31 (-1.25%) , ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) , INCY Incyte $82.30 / -3.14 (-3.68%) , MTEM Molecular Templates $8.68 / -0.16 (-1.81%) , KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) , ICLR Icon $199.11 / +1.67 (+0.85%) , MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) , NVST Envista $31.12 / +1.06 (+3.53%) , EXEL Exelixis $19.32 / +0.17 (+0.89%) , FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) , FOLD Amicus $23.25 / +0.58 (+2.56%) , COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) , BHC Bausch Health $19.06 / +0.42 (+2.25%) , TBIO Translate Bio $22.49 / +0.25 (+1.12%) , STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) , PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZBH TBIO STRO PRAX NVST NKTX MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) 08/04/20 Zimmer Biomet saw incremental improvement in May, June TBIO Translate Bio $22.49 / +0.25 (+1.12%) 10/15/20 Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels 10/07/20 Translate Bio announces upcoming presentations at NACFC 09/08/20 Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005 06/23/20 Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer 09/02/20 Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002 08/25/20 Sutro Biopharma achieves clinical supply milestone with Merck 06/22/20 Sutro Biopharma presents new data on STRO-002 PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 11/17/20 Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21 11/09/20 FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold NVST Envista $31.12 / +1.06 (+3.53%) 10/30/20 Envista rises 10.7% 08/04/20 Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call NKTX Nkarta $33.99 / -0.02 (-0.06%) 11/12/20 Nkarta announces first patient treated in NKX101 trial 11/09/20 Nkarta announces preclinical update on NKX019 10/05/20 Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds 07/24/20 Ra Capital reports 17.2% stake in Nkarta MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 06/22/20 Molecular Templates provides update on Phase 1 study of MT-5111 06/22/20 Molecular Templates highlights ETB platform at AACR Annual Meeting MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA 08/10/20 Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/16/20 Kodiak Sciences completes enrollment of DAZZLE study of KSI-301 10/05/20 Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301 07/10/20 Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study INSM Insmed $39.74 / +0.71 (+1.82%) 12/02/20 Insmed initiates Phase 3 study of Brensocatib in patients with bronchiectasis 11/13/20 Insmed's Brensocatib receives EMA priority medicines designation for NCFBE 10/28/20 Insmed: EC grants marketing authorization for ARIKAYCE 09/07/20 Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM INCY Incyte $82.30 / -3.14 (-3.68%) 11/30/20 MacroGenics achieves $25M in milestones related to retifanlimab collaboration 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement ICLR Icon $199.11 / +1.67 (+0.85%) 10/21/20 Icon says COVID-19 impact reduced in recent months 07/22/20 Icon shareholders vote in favor of all resolutions at annual meeting HRC Hill-Rom $96.12 / -0.16 (-0.17%) 07/28/20 Hill-Rom announces commercial partnership with Aiva for hands-free communication FOLD Amicus $23.25 / +0.58 (+2.56%) 12/01/20 Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease 11/05/20 Amicus plans to initiate rolling BLA for AT-GAA in 2020 11/05/20 Amicus sees FY20 Galafold revenue of $250M-$260M 10/12/20 Amicus announces additional interim clinical data for AT-GTX-501 FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant 07/14/20 Fate Therapeutics announces license agreement with Baylor College of Medicine EXEL Exelixis $19.32 / +0.17 (+0.89%) 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact 11/27/20 Exelixis says Takeda receives approval for CABOMETYX in Japan 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo ENTA Enanta $42.11 / +1.06 (+2.58%) 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL 07/09/20 Enanta announces clinical trial progress for ED-514 DRNA Dicerna $24.45 / -0.31 (-1.25%) 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial 11/16/20 Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD 10/22/20 Dicerna reports 'positive' new interim data from PHYOX3 trial 09/16/20 Dicerna appoints Ling Zeng as chief legal officer COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/16/20 Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2 10/29/20 Bausch Health's rifaximin Receives FDA Orphan Designation ALXN Alexion $122.70 / +0.55 (+0.45%) 11/25/20 Alexion granted orphan status for hematopoietic stem cell treatment 11/20/20 Alexion receives marketing authorization from EC for Ultomiris 100mg 10/12/20 Alexion gets FDA Aaproval for Ultomoris 10/06/20 Alexion expects to raise FY20 revenue guidance by more than $200M CMPS INSM ALXN ENTA NKTX HRC DRNA ZBH INCY MTEM KOD ICLR MCRB NVST EXEL FATE FOLD COGT BHC TBIO STRO PRAX CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg INSM Insmed $39.74 / +0.71 (+1.82%) 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 10/12/20 Stifel Insmed resumed with a Buy at Stifel 04/23/20 JMP Securities JMP reiterates $50 target on Insmed on planned COVID-19 trial ALXN Alexion $122.70 / +0.55 (+0.45%) 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/19/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/05/20 Citi Alexion price target raised to $157 from $145 at Citi ENTA Enanta $42.11 / +1.06 (+2.58%) 11/24/20 RBC Capital Enanta price target lowered to $45 from $52 at RBC Capital 11/24/20 Evercore ISI Evercore cautious on Enanta into 2021, starts with Underperform 11/23/20 Evercore ISI Enanta initiated with an Underperform at Evercore ISI 10/26/20 Roth Capital Enanta price target raised to $107 from $104 at Roth Capital NKTX Nkarta $33.99 / -0.02 (-0.06%) 10/06/20 Mizuho Nkarta CFO departure should not impact shares, says Mizuho 08/04/20 Mizuho Mizuho starts Nkarta with Buy rating, $34 price target 08/04/20 Evercore ISI Nkarta initiated with an Outperform at Evercore ISI 08/04/20 Stifel Nkarta initiated with a Buy at Stifel HRC Hill-Rom $96.12 / -0.16 (-0.17%) 11/04/20 Fly Intel: Top five analyst downgrades 11/04/20 Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21 11/04/20 Needham Hill-Rom downgraded to Hold from Buy at Needham 10/01/20 KeyBanc Hill-Rom price target lowered to $115 from $138 at KeyBanc DRNA Dicerna $24.45 / -0.31 (-1.25%) 08/07/20 H.C. Wainwright Dicerna price target raised to $35 from $32 at H.C. Wainwright 07/01/20 Baird Dicerna elevated to Fresh Pick at Baird 05/12/20 RBC Capital Dicerna initiated with an Outperform at RBC Capital 05/11/20 Truist Dicerna price target raised to $33 from $28 at SunTrust ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) 11/09/20 SVB Leerink Zimmer Biomet price target raised to $167 from $160 at SVB Leerink 11/09/20 Credit Suisse Zimmer Biomet price target raised to $106 from $99 at Credit Suisse 11/09/20 Baird Zimmer Biomet valuation discount to peers hard to justify, says at Baird 11/09/20 Oppenheimer Zimmer Biomet price target raised to $155 from $150 at Oppenheimer INCY Incyte $82.30 / -3.14 (-3.68%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 09/08/20 Jefferies Molecular Templates initiated with a Buy at Jefferies 08/07/20 Molecular Templates files $300M mixed securities shelf 05/12/20 Oppenheimer Molecular Templates price target raised to $22 from $16 at Oppenheimer 03/25/20 Fly Intel: Top five analyst initiations KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/30/20 Fly Intel: Top five analyst downgrades 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral on valuation at JPMorgan 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan 11/16/20 Morgan Stanley Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts ICLR Icon $199.11 / +1.67 (+0.85%) 10/23/20 Deutsche Bank Icon price target raised to $179 from $170 at Deutsche Bank 10/23/20 Mizuho Icon price target raised to $217 from $195 at Mizuho 10/22/20 Credit Suisse Icon price target raised to $235 from $230 at Credit Suisse 07/27/20 Truist SunTrust raises price targets on select late-stage CROs MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler 10/27/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer 10/26/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer NVST Envista $31.12 / +1.06 (+3.53%) 10/30/20 JPMorgan Envista price target raised to $30 from $28 at JPMorgan 10/30/20 Piper Sandler Envista price target raised to $28 from $22 at Piper Sandler 07/31/20 Piper Sandler Envista price target raised to $22 from $20 at Piper Sandler 06/16/20 Fly Intel: Top five analyst initiations EXEL Exelixis $19.32 / +0.17 (+0.89%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) 12/02/20 Barclays Fate Therapeutics price target raised to $70 from $60 at Barclays 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer FOLD Amicus $23.25 / +0.58 (+2.56%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Amicus initiated with a Hold at Berenberg 11/06/20 Baird Amicus price target raised to $25 from $20 at Baird 08/11/20 Citi Amicus price target raised to $20 from $15 at Citi COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays 09/17/20 Fly Intel: Top five analyst upgrades 09/17/20 BofA Bausch Health upgraded to Neutral from Underperform at BofA TBIO Translate Bio $22.49 / +0.25 (+1.12%) 10/04/20 Goldman Sachs Translate Bio initiated with a Buy at Goldman Sachs 07/07/20 H.C. Wainwright Translate Bio price target raised to $32 from $18 at H.C. Wainwright 07/06/20 Fly Intel: Top five analyst initiations 07/06/20 William Blair Translate Bio initiated with an Outperform at William Blair STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 12/02/20 Stifel Sutro Biopharma initiated with a Buy at Stifel 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Wedbush Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform 11/11/20 Wedbush Praxis Precision Medicines initiated with an Outperform at Wedbush ZBH STRO NVST MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $147.88 / +1.77 (+1.21%) 11/06/20 Zimmer Biomet not providing Q4 guidance 11/06/20 Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07 08/04/20 Zimmer Biomet not providing FY20 guidance due to COVID-19 08/04/20 Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c) STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) NVST Envista $31.12 / +1.06 (+3.53%) 10/29/20 Envista reports Q3 adjusted EPS 48c, consensus 9c 07/30/20 Envista reports Q2 adjusted EPS (10c), consensus (22c) MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 11/05/20 Molecular Templates cash, equivalents expected to fund operations into 2H22 11/05/20 Molecular Templates reports Q3 EPS (47c), consensus (55c) 08/06/20 Molecular Templates reports Q2 EPS (68c), consensus (36c) MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/09/20 Kodiak Sciences reports Q3 EPS (80c), consensus (67c) 08/10/20 Kodiak Sciences reports Q2 EPS (58c), consensus (66c) INSM Insmed $39.74 / +0.71 (+1.82%) 10/29/20 Insmed reports Q3 GAAP EPS (63c), consensus (61c) 08/06/20 Insmed reports Q2 EPS (64c), consensus (63c) INCY Incyte $82.30 / -3.14 (-3.68%) 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 08/04/20 Incyte reports Q2 EPS $1.24, consensus 87c 08/03/20 Notable companies reporting before tomorrow's open ICLR Icon $199.11 / +1.67 (+0.85%) 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 07/22/20 Icon sees FY20 EPS $6.00-$6.50, consensus $5.95 07/22/20 Icon reports Q2 adjusted EPS $1.20, consensus $1.10 HRC Hill-Rom $96.12 / -0.16 (-0.17%) 11/06/20 Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38 11/06/20 Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c 11/06/20 Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07 07/31/20 Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46 FOLD Amicus $23.25 / +0.58 (+2.56%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) 07/17/20 Amicus reaffirms 2020 Galafold revenue view $250M-$260M FATE Fate Therapeutics $60.50 / +0.35 (+0.58%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EXEL Exelixis $19.32 / +0.17 (+0.89%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c ENTA Enanta $42.11 / +1.06 (+2.58%) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) 08/04/20 Enanta reports Q3 EPS (71c), consensus (84c) DRNA Dicerna $24.45 / -0.31 (-1.25%) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 08/06/20 Dicerna reports Q2 EPS (43c), consensus 10c COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open ALXN Alexion $122.70 / +0.55 (+0.45%) 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 10/28/20 Notable companies reporting before tomorrow's open 02 Dec 18 Nov 16 Oct 18 Sep 13 Aug 10 Jul 26 Jun 09 Jun 12 May 05 May 04 Dec TBIO FOLD CMPS ALXN TBIO Translate Bio $22.49 / +0.25 (+1.12%) 08/28/20 Sanofi CEO more confident about COVID-19 vaccine candidates, Reuters says FOLD Amicus $23.25 / +0.58 (+2.56%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research ALXN Alexion $122.70 / +0.55 (+0.45%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports TBIO STRO PRAX NVST NKTX MTEM MCRB KOD FOLD ENTA COGT BHC ALXN TBIO Translate Bio $22.49 / +0.25 (+1.12%) 06/24/20 Fly Intel: After-Hours Movers 06/23/20 Fly Intel: Wall Street's top stories for Tuesday 06/23/20 Fly Intel: Wall Street's top stories at midday 06/23/20 Fly Intel: Pre-market Movers STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/03/20 Fly Intel: Wall Street's top stories at midday PRAX Praxis Precision Medicines $43.98 / +1.51 (+3.56%) 10/18/20 Opening Day: Array jumps after $1.05B IPO NVST Envista $31.12 / +1.06 (+3.53%) 10/29/20 Fly Intel: After-Hours Movers 07/30/20 Fly Intel: After-Hours Movers NKTX Nkarta $33.99 / -0.02 (-0.06%) 08/04/20 Zillow, Seagate upgrades among today's top calls on Wall Street 07/20/20 Fly Insider: Idera, ChemoCentryx among week's notable insider trades 07/12/20 Opening Day: Cancer 'killer' Nkarta soars after coming public 07/05/20 Opening Day: Lemonade, Accolade jump in trading debuts MTEM Molecular Templates $8.68 / -0.16 (-1.81%) 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers KOD Kodiak Sciences $130.73 / +0.35 (+0.27%) 11/16/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/24/20 Fly Insider: Kodiak, Camping World among week's notable insider trades FOLD Amicus $23.25 / +0.58 (+2.56%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street ENTA Enanta $42.11 / +1.06 (+2.58%) 11/23/20 Fly Intel: After-Hours Movers COGT Cogent Biosciences $12.15 / +1.63 (+15.49%) 11/30/20 Fly Intel: After-Hours Movers BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/03/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Wall Street's top stories for Thursday 08/06/20 Fly Intel: Wall Street's top stories at midday ALXN Alexion $122.70 / +0.55 (+0.45%) 06/11/20 Biogen, Alexion seen as logical targets for AstraZeneca if Gilead not available 12/01/20 3rd Annual HealthCONx Virtual Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/04/20 Enanta - ENTA 12/10/20 Dicerna - DRNA 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 12/14/20 Nkarta 12/15/20 Hill-Rom ALXN ALXN Alexion $122.70 / +0.55 (+0.45%) 09/15/20 Alexion strength attributed to takeover speculation STRO MCRB INCY CMPS BHC ALXN STRO Sutro Biopharma $16.37 / -0.4 (-2.39%) 11/09/20 Eleven new option listings and two option delistings on November 9th MCRB Seres Therapeutics $25.14 / -1.2 (-4.56%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish INCY Incyte $82.30 / -3.14 (-3.68%) 07/20/20 Early notable gainers among liquid option names on July 20th CMPS Compass Pathways $47.94 / +3.21 (+7.18%) 10/21/20 Eleven new option listings and one option delisting on October 21st BHC Bausch Health $19.06 / +0.42 (+2.25%) 11/06/20 Bausch Health put volume heavy and directionally bearish 10/21/20 Bausch Health call volume above normal and directionally bullish 10/15/20 Bausch Health call volume above normal and directionally bullish 10/08/20 Bausch Health call volume above normal and directionally bullish ALXN Alexion $122.70 / +0.55 (+0.45%) 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish 09/11/20 Alexion call volume above normal and directionally bullish 09/03/20 Largest borrow rate increases among liquid names
Syndicate	Cogent Biosciences 10.256M share Secondary priced at $9.75 » 06:09 12/02/20 12/02 06:09 12/02/20 06:09 COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) The deal size was… The deal size was increased to $100M in common stock from $60M in common stock. Jefferies and Piper Sandler acted as joint book running managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) 02 Dec COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/30/20 Fly Intel: After-Hours Movers 12/01/20 3rd Annual HealthCONx Virtual Conference
Conference/Events	Evercore ISI to hold a virtual conference » 04:55 12/02/20 12/02 04:55 12/02/20 04:55 CMPS Compass Pathways $44.73 / -4.78 (-9.65%) , INSM Insmed $39.05 / +0.03 (+0.08%) , ALXN Alexion $122.16 / +0.19 (+0.16%) , ENTA Enanta $41.12 / +0.01 (+0.02%) , NKTX Nkarta $34.02 / +1.09 (+3.31%) , HRC Hill-Rom $96.26 / +1.325 (+1.40%) , DRNA Dicerna $24.76 / -0.53 (-2.10%) , ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) , INCY Incyte $85.42 / +0.9 (+1.06%) , MTEM Molecular Templates $8.85 / -0.1 (-1.12%) , KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) , ICLR Icon $197.44 / +2.59 (+1.33%) , MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) , NVST Envista $30.06 / +0.31 (+1.04%) , EXEL Exelixis $19.15 / +0.02 (+0.10%) , FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) , FOLD Amicus $22.66 / -0.28 (-1.22%) , COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) , BHC Bausch Health $18.65 / +0.065 (+0.35%) , TBIO Translate Bio $22.25 / +0.03 (+0.14%) , STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) , PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZBH TBIO STRO PRAX NVST NKTX MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) 08/04/20 Zimmer Biomet saw incremental improvement in May, June TBIO Translate Bio $22.25 / +0.03 (+0.14%) 10/15/20 Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels 10/07/20 Translate Bio announces upcoming presentations at NACFC 09/08/20 Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005 06/23/20 Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer 09/02/20 Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002 08/25/20 Sutro Biopharma achieves clinical supply milestone with Merck 06/22/20 Sutro Biopharma presents new data on STRO-002 PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 11/17/20 Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21 11/09/20 FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold NVST Envista $30.06 / +0.31 (+1.04%) 10/30/20 Envista rises 10.7% 08/04/20 Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call NKTX Nkarta $34.02 / +1.09 (+3.31%) 11/12/20 Nkarta announces first patient treated in NKX101 trial 11/09/20 Nkarta announces preclinical update on NKX019 10/05/20 Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds 07/24/20 Ra Capital reports 17.2% stake in Nkarta MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 06/22/20 Molecular Templates provides update on Phase 1 study of MT-5111 06/22/20 Molecular Templates highlights ETB platform at AACR Annual Meeting MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA 08/10/20 Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/16/20 Kodiak Sciences completes enrollment of DAZZLE study of KSI-301 10/05/20 Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301 07/10/20 Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study INSM Insmed $39.05 / +0.03 (+0.08%) 11/13/20 Insmed's Brensocatib receives EMA priority medicines designation for NCFBE 10/28/20 Insmed: EC grants marketing authorization for ARIKAYCE 09/07/20 Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM 07/24/20 Insmed's Arikayce for lung infections receives positive CHMP opinion in EU INCY Incyte $85.42 / +0.9 (+1.06%) 11/30/20 MacroGenics achieves $25M in milestones related to retifanlimab collaboration 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement ICLR Icon $197.44 / +2.59 (+1.33%) 10/21/20 Icon says COVID-19 impact reduced in recent months 07/22/20 Icon shareholders vote in favor of all resolutions at annual meeting HRC Hill-Rom $96.26 / +1.325 (+1.40%) 07/28/20 Hill-Rom announces commercial partnership with Aiva for hands-free communication FOLD Amicus $22.66 / -0.28 (-1.22%) 12/01/20 Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease 11/05/20 Amicus plans to initiate rolling BLA for AT-GAA in 2020 11/05/20 Amicus sees FY20 Galafold revenue of $250M-$260M 10/12/20 Amicus announces additional interim clinical data for AT-GTX-501 FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant 07/14/20 Fate Therapeutics announces license agreement with Baylor College of Medicine EXEL Exelixis $19.15 / +0.02 (+0.10%) 11/27/20 Exelixis says Takeda receives approval for CABOMETYX in Japan 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo ENTA Enanta $41.12 / +0.01 (+0.02%) 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL 07/09/20 Enanta announces clinical trial progress for ED-514 DRNA Dicerna $24.76 / -0.53 (-2.10%) 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial 11/16/20 Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD 10/22/20 Dicerna reports 'positive' new interim data from PHYOX3 trial 09/16/20 Dicerna appoints Ling Zeng as chief legal officer COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/16/20 Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2 10/29/20 Bausch Health's rifaximin Receives FDA Orphan Designation ALXN Alexion $122.16 / +0.19 (+0.16%) 11/25/20 Alexion granted orphan status for hematopoietic stem cell treatment 11/20/20 Alexion receives marketing authorization from EC for Ultomiris 100mg 10/12/20 Alexion gets FDA Aaproval for Ultomoris 10/06/20 Alexion expects to raise FY20 revenue guidance by more than $200M CMPS INSM ALXN ENTA NKTX HRC DRNA ZBH INCY MTEM KOD ICLR MCRB NVST EXEL FATE FOLD COGT BHC TBIO STRO PRAX CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg INSM Insmed $39.05 / +0.03 (+0.08%) 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 10/12/20 Stifel Insmed resumed with a Buy at Stifel 04/23/20 JMP Securities JMP reiterates $50 target on Insmed on planned COVID-19 trial ALXN Alexion $122.16 / +0.19 (+0.16%) 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/19/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/05/20 Citi Alexion price target raised to $157 from $145 at Citi ENTA Enanta $41.12 / +0.01 (+0.02%) 11/24/20 RBC Capital Enanta price target lowered to $45 from $52 at RBC Capital 11/24/20 Evercore ISI Evercore cautious on Enanta into 2021, starts with Underperform 11/23/20 Evercore ISI Enanta initiated with an Underperform at Evercore ISI 10/26/20 Roth Capital Enanta price target raised to $107 from $104 at Roth Capital NKTX Nkarta $34.02 / +1.09 (+3.31%) 10/06/20 Mizuho Nkarta CFO departure should not impact shares, says Mizuho 08/04/20 Mizuho Mizuho starts Nkarta with Buy rating, $34 price target 08/04/20 Evercore ISI Nkarta initiated with an Outperform at Evercore ISI 08/04/20 Stifel Nkarta initiated with a Buy at Stifel HRC Hill-Rom $96.26 / +1.325 (+1.40%) 11/04/20 Fly Intel: Top five analyst downgrades 11/04/20 Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21 11/04/20 Needham Hill-Rom downgraded to Hold from Buy at Needham 10/01/20 KeyBanc Hill-Rom price target lowered to $115 from $138 at KeyBanc DRNA Dicerna $24.76 / -0.53 (-2.10%) 08/07/20 H.C. Wainwright Dicerna price target raised to $35 from $32 at H.C. Wainwright 07/01/20 Baird Dicerna elevated to Fresh Pick at Baird 05/12/20 RBC Capital Dicerna initiated with an Outperform at RBC Capital 05/11/20 Truist Dicerna price target raised to $33 from $28 at SunTrust ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) 11/09/20 SVB Leerink Zimmer Biomet price target raised to $167 from $160 at SVB Leerink 11/09/20 Credit Suisse Zimmer Biomet price target raised to $106 from $99 at Credit Suisse 11/09/20 Baird Zimmer Biomet valuation discount to peers hard to justify, says at Baird 11/09/20 Oppenheimer Zimmer Biomet price target raised to $155 from $150 at Oppenheimer INCY Incyte $85.42 / +0.9 (+1.06%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 09/08/20 Jefferies Molecular Templates initiated with a Buy at Jefferies 08/07/20 Molecular Templates files $300M mixed securities shelf 05/12/20 Oppenheimer Molecular Templates price target raised to $22 from $16 at Oppenheimer 03/25/20 Fly Intel: Top five analyst initiations KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/30/20 Fly Intel: Top five analyst downgrades 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral on valuation at JPMorgan 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan 11/16/20 Morgan Stanley Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts ICLR Icon $197.44 / +2.59 (+1.33%) 10/23/20 Deutsche Bank Icon price target raised to $179 from $170 at Deutsche Bank 10/23/20 Mizuho Icon price target raised to $217 from $195 at Mizuho 10/22/20 Credit Suisse Icon price target raised to $235 from $230 at Credit Suisse 07/27/20 Truist SunTrust raises price targets on select late-stage CROs MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler 10/27/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer 10/26/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer NVST Envista $30.06 / +0.31 (+1.04%) 10/30/20 JPMorgan Envista price target raised to $30 from $28 at JPMorgan 10/30/20 Piper Sandler Envista price target raised to $28 from $22 at Piper Sandler 07/31/20 Piper Sandler Envista price target raised to $22 from $20 at Piper Sandler 06/16/20 Fly Intel: Top five analyst initiations EXEL Exelixis $19.15 / +0.02 (+0.10%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer 11/06/20 Piper Sandler Fate Therapeutics price target raised to $71 from $59 at Piper Sandler FOLD Amicus $22.66 / -0.28 (-1.22%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Amicus initiated with a Hold at Berenberg 11/06/20 Baird Amicus price target raised to $25 from $20 at Baird 08/11/20 Citi Amicus price target raised to $20 from $15 at Citi COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays 09/17/20 Fly Intel: Top five analyst upgrades 09/17/20 BofA Bausch Health upgraded to Neutral from Underperform at BofA TBIO Translate Bio $22.25 / +0.03 (+0.14%) 10/04/20 Goldman Sachs Translate Bio initiated with a Buy at Goldman Sachs 07/07/20 H.C. Wainwright Translate Bio price target raised to $32 from $18 at H.C. Wainwright 07/06/20 Fly Intel: Top five analyst initiations 07/06/20 William Blair Translate Bio initiated with an Outperform at William Blair STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies 07/16/20 Wells Fargo Sutro Biopharma initiated with an Overweight at Wells Fargo PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Wedbush Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform 11/11/20 Wedbush Praxis Precision Medicines initiated with an Outperform at Wedbush ZBH STRO NVST MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $146.00 / -3.175 (-2.13%) 11/06/20 Zimmer Biomet not providing Q4 guidance 11/06/20 Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07 08/04/20 Zimmer Biomet not providing FY20 guidance due to COVID-19 08/04/20 Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c) STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) NVST Envista $30.06 / +0.31 (+1.04%) 10/29/20 Envista reports Q3 adjusted EPS 48c, consensus 9c 07/30/20 Envista reports Q2 adjusted EPS (10c), consensus (22c) MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 11/05/20 Molecular Templates cash, equivalents expected to fund operations into 2H22 11/05/20 Molecular Templates reports Q3 EPS (47c), consensus (55c) 08/06/20 Molecular Templates reports Q2 EPS (68c), consensus (36c) MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/09/20 Kodiak Sciences reports Q3 EPS (80c), consensus (67c) 08/10/20 Kodiak Sciences reports Q2 EPS (58c), consensus (66c) INSM Insmed $39.05 / +0.03 (+0.08%) 10/29/20 Insmed reports Q3 GAAP EPS (63c), consensus (61c) 08/06/20 Insmed reports Q2 EPS (64c), consensus (63c) INCY Incyte $85.42 / +0.9 (+1.06%) 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 08/04/20 Incyte reports Q2 EPS $1.24, consensus 87c 08/03/20 Notable companies reporting before tomorrow's open ICLR Icon $197.44 / +2.59 (+1.33%) 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 07/22/20 Icon sees FY20 EPS $6.00-$6.50, consensus $5.95 07/22/20 Icon reports Q2 adjusted EPS $1.20, consensus $1.10 HRC Hill-Rom $96.26 / +1.325 (+1.40%) 11/06/20 Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38 11/06/20 Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c 11/06/20 Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07 07/31/20 Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46 FOLD Amicus $22.66 / -0.28 (-1.22%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) 07/17/20 Amicus reaffirms 2020 Galafold revenue view $250M-$260M FATE Fate Therapeutics $60.15 / +1.68 (+2.87%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EXEL Exelixis $19.15 / +0.02 (+0.10%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c ENTA Enanta $41.12 / +0.01 (+0.02%) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) 08/04/20 Enanta reports Q3 EPS (71c), consensus (84c) DRNA Dicerna $24.76 / -0.53 (-2.10%) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 08/06/20 Dicerna reports Q2 EPS (43c), consensus 10c COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open ALXN Alexion $122.16 / +0.19 (+0.16%) 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 10/28/20 Notable companies reporting before tomorrow's open 02 Dec 18 Nov 16 Oct 18 Sep 13 Aug 10 Jul 26 Jun 09 Jun 12 May 05 May 04 Dec TBIO FOLD CMPS ALXN TBIO Translate Bio $22.25 / +0.03 (+0.14%) 08/28/20 Sanofi CEO more confident about COVID-19 vaccine candidates, Reuters says FOLD Amicus $22.66 / -0.28 (-1.22%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research ALXN Alexion $122.16 / +0.19 (+0.16%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports TBIO STRO PRAX NVST NKTX MTEM MCRB KOD FOLD ENTA COGT BHC ALXN TBIO Translate Bio $22.25 / +0.03 (+0.14%) 06/24/20 Fly Intel: After-Hours Movers 06/23/20 Fly Intel: Wall Street's top stories for Tuesday 06/23/20 Fly Intel: Wall Street's top stories at midday 06/23/20 Fly Intel: Pre-market Movers STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/03/20 Fly Intel: Wall Street's top stories at midday PRAX Praxis Precision Medicines $42.43 / +1.49 (+3.64%) 10/18/20 Opening Day: Array jumps after $1.05B IPO NVST Envista $30.06 / +0.31 (+1.04%) 10/29/20 Fly Intel: After-Hours Movers 07/30/20 Fly Intel: After-Hours Movers NKTX Nkarta $34.02 / +1.09 (+3.31%) 08/04/20 Zillow, Seagate upgrades among today's top calls on Wall Street 07/20/20 Fly Insider: Idera, ChemoCentryx among week's notable insider trades 07/12/20 Opening Day: Cancer 'killer' Nkarta soars after coming public 07/05/20 Opening Day: Lemonade, Accolade jump in trading debuts MTEM Molecular Templates $8.85 / -0.1 (-1.12%) 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers KOD Kodiak Sciences $130.37 / -6.31 (-4.62%) 11/16/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/24/20 Fly Insider: Kodiak, Camping World among week's notable insider trades FOLD Amicus $22.66 / -0.28 (-1.22%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street ENTA Enanta $41.12 / +0.01 (+0.02%) 11/23/20 Fly Intel: After-Hours Movers COGT Cogent Biosciences $10.52 / +0.56 (+5.62%) 11/30/20 Fly Intel: After-Hours Movers BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/03/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Wall Street's top stories for Thursday 08/06/20 Fly Intel: Wall Street's top stories at midday ALXN Alexion $122.16 / +0.19 (+0.16%) 06/11/20 Biogen, Alexion seen as logical targets for AstraZeneca if Gilead not available 12/01/20 3rd Annual HealthCONx Virtual Conference 12/02/20 32nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/04/20 Enanta - ENTA 12/10/20 Dicerna - DRNA 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 12/14/20 Nkarta 12/15/20 Hill-Rom ALXN ALXN Alexion $122.16 / +0.19 (+0.16%) 09/15/20 Alexion strength attributed to takeover speculation STRO MCRB INCY CMPS BHC ALXN STRO Sutro Biopharma $16.76 / -0.32 (-1.87%) 11/09/20 Eleven new option listings and two option delistings on November 9th MCRB Seres Therapeutics $26.34 / -1.2 (-4.36%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish INCY Incyte $85.42 / +0.9 (+1.06%) 07/20/20 Early notable gainers among liquid option names on July 20th CMPS Compass Pathways $44.73 / -4.78 (-9.65%) 10/21/20 Eleven new option listings and one option delisting on October 21st BHC Bausch Health $18.65 / +0.065 (+0.35%) 11/06/20 Bausch Health put volume heavy and directionally bearish 10/21/20 Bausch Health call volume above normal and directionally bullish 10/15/20 Bausch Health call volume above normal and directionally bullish 10/08/20 Bausch Health call volume above normal and directionally bullish ALXN Alexion $122.16 / +0.19 (+0.16%) 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish 09/11/20 Alexion call volume above normal and directionally bullish 09/03/20 Largest borrow rate increases among liquid names

Conference/Events	Evercore ISI to hold a virtual conference » 08:22 12/01/20 12/01 08:22 12/01/20 08:22 CMPS Compass Pathways $49.60 / +2.26 (+4.77%) , INSM Insmed $39.02 / -0.8 (-2.01%) , ALXN Alexion $121.96 / -2.03 (-1.64%) , ENTA Enanta $41.32 / -1.5 (-3.50%) , NKTX Nkarta $32.91 / -1.23 (-3.60%) , HRC Hill-Rom $94.86 / -0.71 (-0.74%) , DRNA Dicerna $25.32 / +0.79 (+3.22%) , ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) , INCY Incyte $84.52 / +1.33 (+1.60%) , MTEM Molecular Templates $8.93 / -0.18 (-1.98%) , KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) , ICLR Icon $194.85 / +4.45 (+2.34%) , MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) , NVST Envista $29.75 / +0.14 (+0.47%) , EXEL Exelixis $19.16 / -0.26 (-1.34%) , FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) , FOLD Amicus $22.94 / -0.31 (-1.33%) , COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) , BHC Bausch Health $18.58 / -0.97 (-4.96%) , TBIO Translate Bio $22.24 / +2.9 (+14.99%) , STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) , PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZBH TBIO STRO PRAX NVST NKTX MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) 08/04/20 Zimmer Biomet saw incremental improvement in May, June TBIO Translate Bio $22.24 / +2.9 (+14.99%) 10/15/20 Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels 10/07/20 Translate Bio announces upcoming presentations at NACFC 09/08/20 Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005 06/23/20 Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer 09/02/20 Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002 08/25/20 Sutro Biopharma achieves clinical supply milestone with Merck 06/22/20 Sutro Biopharma presents new data on STRO-002 PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 11/17/20 Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21 11/09/20 FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold NVST Envista $29.75 / +0.14 (+0.47%) 10/30/20 Envista rises 10.7% 08/04/20 Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call NKTX Nkarta $32.91 / -1.23 (-3.60%) 11/12/20 Nkarta announces first patient treated in NKX101 trial 11/09/20 Nkarta announces preclinical update on NKX019 10/05/20 Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds 07/24/20 Ra Capital reports 17.2% stake in Nkarta MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 06/22/20 Molecular Templates provides update on Phase 1 study of MT-5111 06/22/20 Molecular Templates highlights ETB platform at AACR Annual Meeting MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA 08/10/20 Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/16/20 Kodiak Sciences completes enrollment of DAZZLE study of KSI-301 10/05/20 Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301 07/10/20 Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study INSM Insmed $39.02 / -0.8 (-2.01%) 11/13/20 Insmed's Brensocatib receives EMA priority medicines designation for NCFBE 10/28/20 Insmed: EC grants marketing authorization for ARIKAYCE 09/07/20 Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM 07/24/20 Insmed's Arikayce for lung infections receives positive CHMP opinion in EU INCY Incyte $84.52 / +1.33 (+1.60%) 11/30/20 MacroGenics achieves $25M in milestones related to retifanlimab collaboration 11/19/20 Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination 11/11/20 Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement ICLR Icon $194.85 / +4.45 (+2.34%) 10/21/20 Icon says COVID-19 impact reduced in recent months 07/22/20 Icon shareholders vote in favor of all resolutions at annual meeting HRC Hill-Rom $94.86 / -0.71 (-0.74%) 07/28/20 Hill-Rom announces commercial partnership with Aiva for hands-free communication FOLD Amicus $22.94 / -0.31 (-1.33%) 12/01/20 Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease 11/05/20 Amicus plans to initiate rolling BLA for AT-GAA in 2020 11/05/20 Amicus sees FY20 Galafold revenue of $250M-$260M 10/12/20 Amicus announces additional interim clinical data for AT-GTX-501 FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) 11/16/20 Fate Therapeutics director sells 25K shares of common stock 08/19/20 Fate Therapeutics appoints Edward Dulac as CFO 08/12/20 Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant 07/14/20 Fate Therapeutics announces license agreement with Baylor College of Medicine EXEL Exelixis $19.16 / -0.26 (-1.34%) 11/27/20 Exelixis says Takeda receives approval for CABOMETYX in Japan 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo ENTA Enanta $41.32 / -1.5 (-3.50%) 09/14/20 Enanta initiates Phase 1 clinical study of EDP-297 08/28/20 Enanta to present data from hepatitis B virus, NASH programs at EASL 07/09/20 Enanta announces clinical trial progress for ED-514 DRNA Dicerna $25.32 / +0.79 (+3.22%) 11/16/20 Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial 11/16/20 Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD 10/22/20 Dicerna reports 'positive' new interim data from PHYOX3 trial 09/16/20 Dicerna appoints Ling Zeng as chief legal officer COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 11/12/20 Compass Pathways expects cash, cash equivalents to fund operations into 2023 11/09/20 Compass Pathways joins the Psychiatry Consortium 10/23/20 Compass Pathways CEO says 'focus is on transforming mental healthcare' 10/05/20 Citron touts mental health company Compass Pathways, sets $100 target on shares BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/16/20 Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2 10/29/20 Bausch Health's rifaximin Receives FDA Orphan Designation ALXN Alexion $121.96 / -2.03 (-1.64%) 11/25/20 Alexion granted orphan status for hematopoietic stem cell treatment 11/20/20 Alexion receives marketing authorization from EC for Ultomiris 100mg 10/12/20 Alexion gets FDA Aaproval for Ultomoris 10/06/20 Alexion expects to raise FY20 revenue guidance by more than $200M CMPS INSM ALXN ENTA NKTX HRC DRNA ZBH INCY MTEM KOD ICLR MCRB NVST EXEL FATE FOLD COGT BHC TBIO STRO PRAX CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 10/14/20 H.C. Wainwright Compass Pathways initiated with a Buy at H.C. Wainwright 10/13/20 Evercore ISI Compass Pathways initiated with an Outperform at Evercore ISI 10/13/20 Canaccord Compass Pathways initiated with a Buy at Canaccord 10/13/20 Berenberg Compass Pathways initiated with a Buy at Berenberg INSM Insmed $39.02 / -0.8 (-2.01%) 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 11/23/20 Evercore ISI Insmed resumed with an Outperform at Evercore ISI 10/12/20 Stifel Insmed resumed with a Buy at Stifel 04/23/20 JMP Securities JMP reiterates $50 target on Insmed on planned COVID-19 trial ALXN Alexion $121.96 / -2.03 (-1.64%) 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/19/20 Bernstein Alexion initiated with a Market Perform at Bernstein 11/05/20 Citi Alexion price target raised to $157 from $145 at Citi ENTA Enanta $41.32 / -1.5 (-3.50%) 11/24/20 RBC Capital Enanta price target lowered to $45 from $52 at RBC Capital 11/24/20 Evercore ISI Evercore cautious on Enanta into 2021, starts with Underperform 11/23/20 Evercore ISI Enanta initiated with an Underperform at Evercore ISI 10/26/20 Roth Capital Enanta price target raised to $107 from $104 at Roth Capital NKTX Nkarta $32.91 / -1.23 (-3.60%) 10/06/20 Mizuho Nkarta CFO departure should not impact shares, says Mizuho 08/04/20 Mizuho Mizuho starts Nkarta with Buy rating, $34 price target 08/04/20 Evercore ISI Nkarta initiated with an Outperform at Evercore ISI 08/04/20 Stifel Nkarta initiated with a Buy at Stifel HRC Hill-Rom $94.86 / -0.71 (-0.74%) 11/04/20 Fly Intel: Top five analyst downgrades 11/04/20 Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21 11/04/20 Needham Hill-Rom downgraded to Hold from Buy at Needham 10/01/20 KeyBanc Hill-Rom price target lowered to $115 from $138 at KeyBanc DRNA Dicerna $25.32 / +0.79 (+3.22%) 08/07/20 H.C. Wainwright Dicerna price target raised to $35 from $32 at H.C. Wainwright 07/01/20 Baird Dicerna elevated to Fresh Pick at Baird 05/12/20 RBC Capital Dicerna initiated with an Outperform at RBC Capital 05/11/20 Truist Dicerna price target raised to $33 from $28 at SunTrust ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) 11/09/20 SVB Leerink Zimmer Biomet price target raised to $167 from $160 at SVB Leerink 11/09/20 Credit Suisse Zimmer Biomet price target raised to $106 from $99 at Credit Suisse 11/09/20 Baird Zimmer Biomet valuation discount to peers hard to justify, says at Baird 11/09/20 Oppenheimer Zimmer Biomet price target raised to $155 from $150 at Oppenheimer INCY Incyte $84.52 / +1.33 (+1.60%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 09/08/20 Jefferies Molecular Templates initiated with a Buy at Jefferies 08/07/20 Molecular Templates files $300M mixed securities shelf 05/12/20 Oppenheimer Molecular Templates price target raised to $22 from $16 at Oppenheimer 03/25/20 Fly Intel: Top five analyst initiations KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/30/20 Fly Intel: Top five analyst downgrades 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral on valuation at JPMorgan 11/30/20 JPMorgan Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan 11/16/20 Morgan Stanley Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts ICLR Icon $194.85 / +4.45 (+2.34%) 10/23/20 Deutsche Bank Icon price target raised to $179 from $170 at Deutsche Bank 10/23/20 Mizuho Icon price target raised to $217 from $195 at Mizuho 10/22/20 Credit Suisse Icon price target raised to $235 from $230 at Credit Suisse 07/27/20 Truist SunTrust raises price targets on select late-stage CROs MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler 10/27/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer 10/26/20 Oppenheimer Seres Therapeutics price target raised to $34 from $29 at Oppenheimer NVST Envista $29.75 / +0.14 (+0.47%) 10/30/20 JPMorgan Envista price target raised to $30 from $28 at JPMorgan 10/30/20 Piper Sandler Envista price target raised to $28 from $22 at Piper Sandler 07/31/20 Piper Sandler Envista price target raised to $22 from $20 at Piper Sandler 06/16/20 Fly Intel: Top five analyst initiations EXEL Exelixis $19.16 / -0.26 (-1.34%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) 11/24/20 Truist Fate Therapeutics price target raised to $65 from $40 at Truist 11/09/20 Citi Fate Therapeutics price target raised to $63 from $40 at Citi 11/08/20 Oppenheimer Fate Therapeutics price target raised to $60 from $40 at Oppenheimer 11/06/20 Piper Sandler Fate Therapeutics price target raised to $71 from $59 at Piper Sandler FOLD Amicus $22.94 / -0.31 (-1.33%) 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Amicus initiated with a Hold at Berenberg 11/06/20 Baird Amicus price target raised to $25 from $20 at Baird 08/11/20 Citi Amicus price target raised to $20 from $15 at Citi COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays 09/17/20 Fly Intel: Top five analyst upgrades 09/17/20 BofA Bausch Health upgraded to Neutral from Underperform at BofA TBIO Translate Bio $22.24 / +2.9 (+14.99%) 10/04/20 Goldman Sachs Translate Bio initiated with a Buy at Goldman Sachs 07/07/20 H.C. Wainwright Translate Bio price target raised to $32 from $18 at H.C. Wainwright 07/06/20 Fly Intel: Top five analyst initiations 07/06/20 William Blair Translate Bio initiated with an Outperform at William Blair STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies 07/16/20 Wells Fargo Sutro Biopharma initiated with an Overweight at Wells Fargo PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations 11/11/20 Wedbush Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform 11/11/20 Wedbush Praxis Precision Medicines initiated with an Outperform at Wedbush ZBH STRO NVST MTEM MCRB KOD INSM INCY ICLR HRC FOLD FATE EXEL ENTA DRNA COGT CMPS BHC ALXN ZBH Zimmer Biomet $149.21 / -0.79 (-0.53%) 11/06/20 Zimmer Biomet not providing Q4 guidance 11/06/20 Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07 08/04/20 Zimmer Biomet not providing FY20 guidance due to COVID-19 08/04/20 Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c) STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) NVST Envista $29.75 / +0.14 (+0.47%) 10/29/20 Envista reports Q3 adjusted EPS 48c, consensus 9c 07/30/20 Envista reports Q2 adjusted EPS (10c), consensus (22c) MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 11/05/20 Molecular Templates cash, equivalents expected to fund operations into 2H22 11/05/20 Molecular Templates reports Q3 EPS (47c), consensus (55c) 08/06/20 Molecular Templates reports Q2 EPS (68c), consensus (36c) MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/09/20 Kodiak Sciences reports Q3 EPS (80c), consensus (67c) 08/10/20 Kodiak Sciences reports Q2 EPS (58c), consensus (66c) INSM Insmed $39.02 / -0.8 (-2.01%) 10/29/20 Insmed reports Q3 GAAP EPS (63c), consensus (61c) 08/06/20 Insmed reports Q2 EPS (64c), consensus (63c) INCY Incyte $84.52 / +1.33 (+1.60%) 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c 08/04/20 Incyte reports Q2 EPS $1.24, consensus 87c 08/03/20 Notable companies reporting before tomorrow's open ICLR Icon $194.85 / +4.45 (+2.34%) 10/21/20 Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50 10/21/20 Icon reports Q3 EPS $1.72, consensus $1.53 07/22/20 Icon sees FY20 EPS $6.00-$6.50, consensus $5.95 07/22/20 Icon reports Q2 adjusted EPS $1.20, consensus $1.10 HRC Hill-Rom $94.86 / -0.71 (-0.74%) 11/06/20 Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38 11/06/20 Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c 11/06/20 Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07 07/31/20 Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46 FOLD Amicus $22.94 / -0.31 (-1.33%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) 07/17/20 Amicus reaffirms 2020 Galafold revenue view $250M-$260M FATE Fate Therapeutics $58.47 / +0.54 (+0.93%) 11/05/20 Fate Therapeutics reports Q3 EPS (40c), consensus (36c) 08/05/20 Fate Therapeutics reports Q2 EPS (35c), consensus (27c) EXEL Exelixis $19.16 / -0.26 (-1.34%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c ENTA Enanta $41.32 / -1.5 (-3.50%) 11/23/20 Enanta reports Q4 EPS ($1.46), consensus (95c) 08/04/20 Enanta reports Q3 EPS (71c), consensus (84c) DRNA Dicerna $25.32 / +0.79 (+3.22%) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 08/06/20 Dicerna reports Q2 EPS (43c), consensus 10c COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 11/12/20 Compass Pathways reports Q3 EPS ($1.30), consensus (56c) BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open ALXN Alexion $121.96 / -2.03 (-1.64%) 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 10/28/20 Notable companies reporting before tomorrow's open 02 Dec 18 Nov 16 Oct 18 Sep 13 Aug 10 Jul 26 Jun 09 Jun 12 May 05 May 04 Dec TBIO FOLD CMPS ALXN TBIO Translate Bio $22.24 / +2.9 (+14.99%) 08/28/20 Sanofi CEO more confident about COVID-19 vaccine candidates, Reuters says FOLD Amicus $22.94 / -0.31 (-1.33%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 10/05/20 Compass Pathways named a long idea with $100 price target by Citron Research ALXN Alexion $121.96 / -2.03 (-1.64%) 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports TBIO STRO PRAX NVST NKTX MTEM MCRB KOD FOLD ENTA COGT BHC ALXN TBIO Translate Bio $22.24 / +2.9 (+14.99%) 06/24/20 Fly Intel: After-Hours Movers 06/23/20 Fly Intel: Wall Street's top stories for Tuesday 06/23/20 Fly Intel: Wall Street's top stories at midday 06/23/20 Fly Intel: Pre-market Movers STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/03/20 Fly Intel: Wall Street's top stories at midday PRAX Praxis Precision Medicines $40.94 / +0.54 (+1.34%) 10/18/20 Opening Day: Array jumps after $1.05B IPO NVST Envista $29.75 / +0.14 (+0.47%) 10/29/20 Fly Intel: After-Hours Movers 07/30/20 Fly Intel: After-Hours Movers NKTX Nkarta $32.91 / -1.23 (-3.60%) 08/04/20 Zillow, Seagate upgrades among today's top calls on Wall Street 07/20/20 Fly Insider: Idera, ChemoCentryx among week's notable insider trades 07/12/20 Opening Day: Cancer 'killer' Nkarta soars after coming public 07/05/20 Opening Day: Lemonade, Accolade jump in trading debuts MTEM Molecular Templates $8.93 / -0.18 (-1.98%) 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Wall Street's top stories for Monday 08/10/20 Fly Intel: Wall Street's top stories at midday 08/10/20 Fly Intel: Pre-market Movers KOD Kodiak Sciences $136.67 / +1.14 (+0.84%) 11/16/20 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades 08/24/20 Fly Insider: Kodiak, Camping World among week's notable insider trades FOLD Amicus $22.94 / -0.31 (-1.33%) 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street ENTA Enanta $41.32 / -1.5 (-3.50%) 11/23/20 Fly Intel: After-Hours Movers COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/30/20 Fly Intel: After-Hours Movers BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/03/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Wall Street's top stories for Thursday 08/06/20 Fly Intel: Wall Street's top stories at midday ALXN Alexion $121.96 / -2.03 (-1.64%) 06/11/20 Biogen, Alexion seen as logical targets for AstraZeneca if Gilead not available 12/01/20 3rd Annual HealthCONx Virtual Conference 12/02/20 32nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/04/20 Enanta - ENTA 12/10/20 Dicerna - DRNA 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 12/14/20 Nkarta ALXN ALXN Alexion $121.96 / -2.03 (-1.64%) 09/15/20 Alexion strength attributed to takeover speculation STRO MCRB INCY CMPS BHC ALXN STRO Sutro Biopharma $17.08 / -0.02 (-0.12%) 11/09/20 Eleven new option listings and two option delistings on November 9th MCRB Seres Therapeutics $27.58 / -1.39 (-4.80%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish INCY Incyte $84.52 / +1.33 (+1.60%) 07/20/20 Early notable gainers among liquid option names on July 20th CMPS Compass Pathways $49.60 / +2.26 (+4.77%) 10/21/20 Eleven new option listings and one option delisting on October 21st BHC Bausch Health $18.58 / -0.97 (-4.96%) 11/06/20 Bausch Health put volume heavy and directionally bearish 10/21/20 Bausch Health call volume above normal and directionally bullish 10/15/20 Bausch Health call volume above normal and directionally bullish 10/08/20 Bausch Health call volume above normal and directionally bullish ALXN Alexion $121.96 / -2.03 (-1.64%) 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish 09/11/20 Alexion call volume above normal and directionally bullish 09/03/20 Largest borrow rate increases among liquid names
On The Fly	Fly Intel: After-Hours Movers » 18:26 11/30/20 11/30 18:26 11/30/20 18:26 NCNA NuCana $4.49 / -0.01 (-0.22%) , TSLA Tesla $567.00 / -18.77 (-3.20%) , MRNA Moderna $152.93 / +25.97 (+20.46%) , NOAH Noah Holdings $29.53 / -4.12 (-12.24%) , ZM Zoom Video $479.28 / +7.98 (+1.69%) , ARRY Array Technologies $45.29 / -1.86 (-3.94%) , DADA Dada Nexus $57.97 / +2.3899 (+4.30%) , COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) , FOUR Shift4 Payments $61.23 / -0.43 (-0.70%) , OSH Oak Street Health $47.17 / +0.17 (+0.36%) , NOVA Sunnova Energy $40.52 / -4.43 (-9.86%) , NTLA Intellia Therapeutics $39.28 / -0.07 (-0.18%) Check out this evening's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZM TSLA OSH NTLA NOVA NOAH NCNA MRNA FOUR DADA COGT ARRY ZM Zoom Video $479.28 / +7.98 (+1.69%) 11/30/20 Zoom Video CFO says Q3 was front-end loaded, Q4 to be back-end loaded 11/30/20 Zoom Video falls 5% to $456 after Q3 earnings, Q4 guidance 11/30/20 Zoom Video reports Q3 customers with over $100M in TTM up 136% 11/23/20 Lumen, Zoom Video expand partnership TSLA Tesla $567.00 / -18.77 (-3.20%) 11/30/20 Tesla jumps 5% to $595.74 after S&P/DJI disclosure regarding its S&P500 addition 11/30/20 Tesla to be added to S&P 500 index at full float-adjusted market capitalization 11/18/20 Tesla CEO says 'only publicly traded stock I own is Tesla' 11/18/20 EU passenger car registrations down 7.8% in October OSH Oak Street Health $47.17 / +0.17 (+0.36%) 09/17/20 Oak Street Health falls -7.4% NTLA Intellia Therapeutics $39.28 / -0.07 (-0.18%) 11/11/20 Intellia receives grant to develop CRISPR/Cas9 in vivo SCD treatments 11/09/20 Intellia Therapeutics doses first patient in trial of NTLA-2001 11/05/20 Intellia Therapeutics announces upcoming milestones 11/05/20 Intellia Therapeutics expects cash to fund expenses through next 24 months NOVA Sunnova Energy $40.52 / -4.43 (-9.86%) 10/14/20 Sunnova Energy expands SunSafe, +SunSafe solar and storage offerings 09/30/20 Sunnova Energy rises 9.9% 09/29/20 Sunnova falls after Spruce Point issues short report with $5-$8 target 09/29/20 Spruce Point issues Strong Sell opinion on Sunnova Energy NOAH Noah Holdings $29.53 / -4.12 (-12.24%) 11/30/20 Noah Holdings announces $100M share repurchase program NCNA NuCana $4.49 / -0.01 (-0.22%) 11/30/20 NuCana announces final results from Acelarin plus cisplatin study published MRNA Moderna $152.93 / +25.97 (+20.46%) 11/30/20 Moderna submits emergency use authorization request to FDA for COVID-19 vaccine 11/30/20 Moderna will submit for Emergency Use Authorization with FDA 11/30/20 Moderna reports vaccine efficacy against COVID-19 of 94.1% 11/29/20 Moderna announces amendment to COVID vaccine supply agreement with U.K. FOUR Shift4 Payments $61.23 / -0.43 (-0.70%) 11/05/20 Shift4 Payments acquires 3dcart ecommerce platform, terms not disclosed 10/14/20 Shift4 Payments sees Q3 payment volume $7.0B-$7.1B 10/06/20 Agilysys, Shift4 Payments announce extension of hospitality partnership 09/11/20 Shift4 Payments falls -6.9% DADA Dada Nexus $57.97 / +2.3899 (+4.30%) 11/13/20 Dada Group announces 'record sales' during 2020 Singles Day Festival 08/14/20 Tiger Global takes stake in ZoomInfo during Q2, exits iQIYI 07/29/20 Dada Group launches Dada Now delivery platform 07/24/20 Dada Group expands strategic partnership with CR Vanguard COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson ARRY Array Technologies $45.29 / -1.86 (-3.94%) 11/30/20 Array Technologies announces 1GW purchase agreement with RP Construction NCNA TSLA MRNA NOAH ZM ARRY DADA COGT FOUR OSH NOVA NTLA NCNA NuCana $4.49 / -0.01 (-0.22%) 11/24/20 H.C. Wainwright NuCana price target lowered to $15 from $17 at H.C. Wainwright 10/22/20 Truist NuCana initiated with a Buy at Truist 10/22/20 Truist NuCana initiated with a Buy at Truist 08/21/20 Piper Sandler NuCana price target raised to $17 from $15 at Piper Sandler TSLA Tesla $567.00 / -18.77 (-3.20%) 11/27/20 BofA BofA positive on long-term share gains for NIO Inc. after hosting calls 11/18/20 Fly Intel: Top five analyst upgrades 11/18/20 Morgan Stanley Morgan Stanley upgrades Tesla on 'profound model shift' to recurring sales 11/18/20 Morgan Stanley Tesla upgraded to Overweight from Equal Weight at Morgan Stanley MRNA Moderna $152.93 / +25.97 (+20.46%) 11/30/20 Wells Fargo Moderna price target raised to $129 from $92 at Wells Fargo 11/27/20 Argus AstraZeneca's COVID vaccine faces high bar for FDA authorization, says Argus 11/25/20 Goldman Sachs Moderna price target raised to $139 from $107 at Goldman Sachs 11/23/20 Fly Intel: Top five analyst initiations NOAH Noah Holdings $29.53 / -4.12 (-12.24%) 07/10/20 Citi Citi boosts Noah Holdings target, opens 'positive catalyst watch' 03/30/20 Citi Noah Holdings upgraded to Buy from Neutral at Citi 02/11/20 Citi Citi downgrades Noah Holdings to Neutral on coronavirus vulnerability 02/11/20 Citi Noah Holdings downgraded to Neutral from Buy at Citi ZM Zoom Video $479.28 / +7.98 (+1.69%) 11/30/20 Northland Plantronics price target raised to $40 from $30 at Northland 11/25/20 Stifel Stifel says Salesforce for Slack at $20B would be 'expensive,' but 'digestible' 11/10/20 Mizuho Zoom Video selloff yesterday a buying opportunity, says Mizuho 10/26/20 Stifel SAP news impact may be company-specific for software sector, says Stifel ARRY Array Technologies $45.29 / -1.86 (-3.94%) 11/09/20 Fly Intel: Top five analyst initiations 11/09/20 Morgan Stanley Array Technologies initiated with an Underweight at Morgan Stanley 11/09/20 UBS Array Technologies initiated with a Neutral at UBS 11/09/20 Oppenheimer Array Technologies initiated with a Perform at Oppenheimer DADA Dada Nexus $57.97 / +2.3899 (+4.30%) 11/11/20 Fly Intel: Top five analyst upgrades 11/11/20 Goldman Sachs Goldman Sachs upgrades Dada Nexus to Buy on online grocery adoption in China 11/11/20 Goldman Sachs Dada Nexus upgraded to Buy from Neutral at Goldman Sachs 10/29/20 New Street Dada Nexus initiated with a Buy at New Street COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg FOUR Shift4 Payments $61.23 / -0.43 (-0.70%) 10/14/20 Truist Shift4 Payments price target raised to $70 from $60 at Truist 10/14/20 Compass Point Shift4 Payments upgraded to Neutral after pre-announcement at Compass Point 10/14/20 Compass Point Shift4 Payments upgraded to Neutral from Sell at Compass Point 10/08/20 RBC Capital Shift4 Payments price target raised to $63 from $49 at RBC Capital OSH Oak Street Health $47.17 / +0.17 (+0.36%) 11/11/20 Piper Sandler Oak Street Health price target raised to $59 from $54 at Piper Sandler 11/11/20 SVB Leerink Oak Street Health price target raised to $78 from $55 at SVB Leerink 11/11/20 Baird Oak Street Health price target raised to $60 from $55 at Baird 10/13/20 Truist Truist raises price targets on select Healthcare Services names NOVA Sunnova Energy $40.52 / -4.43 (-9.86%) 11/09/20 Goldman Sachs Sunnova Energy upgraded to Conviction Buy from Buy at Goldman Sachs 10/27/20 B. Riley Securities Sunnova Energy price target raised to $33 from $30 at B. Riley Securities 10/26/20 Credit Suisse Sunnova Energy price target raised to $38 from $26 at Credit Suisse 10/22/20 Baird Baird a buyer of solar stocks insulated from supply chain disruptions NTLA Intellia Therapeutics $39.28 / -0.07 (-0.18%) 10/27/20 Truist Intellia Therapeutics initiated with a Buy at Truist 10/27/20 Summer Street Intellia Therapeutics initiated with a Buy at Summer Street 10/19/20 Roth Capital Intellia Therapeutics price target raised to $26 from $16 at Roth Capital 10/14/20 Fly Intel: Top five analyst initiations ZM TSLA OSH NTLA NOVA NCNA MRNA FOUR DADA COGT ZM Zoom Video $479.28 / +7.98 (+1.69%) 11/30/20 Zoom Video raises FY21 EPS view to $2.87-$2.97 from $2.40-$2.47 11/30/20 Zoom Video sees Q4 EPS 77c-79c, consensus 66c 11/30/20 Zoom Video reports Q3 EPS 99c, consensus 76c 11/30/20 Notable companies reporting after market close TSLA Tesla $567.00 / -18.77 (-3.20%) 10/21/20 Tesla reports Q3 non-GAAP EPS 76c, consensus 56c 10/21/20 Notable companies reporting after market close 07/22/20 Tesla reports Q2 adjusted EPS 50c, consensus (11c) 07/22/20 Notable companies reporting after market close OSH Oak Street Health $47.17 / +0.17 (+0.36%) 11/09/20 Oak Street Health sees FY20 revenue $854M-$858M, consensus $850.17M 11/09/20 Oak Street Health reports Q3 EPS (15c), consensus (18c) NTLA Intellia Therapeutics $39.28 / -0.07 (-0.18%) 11/05/20 Intellia Therapeutics reports Q3 EPS (47c), consensus (59c) 08/06/20 Intellia Therapeutics reports Q2 EPS (61c), consensus (69c) NOVA Sunnova Energy $40.52 / -4.43 (-9.86%) 10/28/20 Sunnova sees FY21 adjusted EBITDA $77M-$83M 10/28/20 Sunnova backs FY20 adjusted EBITDA view $58M-$62M 10/28/20 Sunnova reports Q3 EPS (73c), consensus (15c) 10/28/20 Notable companies reporting after market close NCNA NuCana $4.49 / -0.01 (-0.22%) 11/19/20 NuCana reports Q3 EPS GBP( 0.24) versus GBP (0.12) in Q319 MRNA Moderna $152.93 / +25.97 (+20.46%) 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 08/05/20 Moderna reports Q2 EPS (31c), consensus (35c) FOUR Shift4 Payments $61.23 / -0.43 (-0.70%) 11/05/20 Shift4 Payments reports Q3 EPS (12c), consensus 5c 11/04/20 Notable companies reporting before tomorrow's open 08/06/20 Shift4 Payments sees Q4 revenue $75M-$79M DADA Dada Nexus $57.97 / +2.3899 (+4.30%) 11/19/20 Dada Nexus sees Q4 revenue RMB2B-RMB2.1B 11/19/20 Dada Nexus reports Q3 adjusted EPS RMB0.36 vs RMB1.71 last year 08/24/20 Dada Nexus sees Q3 revenue RMB 1.28B-1.34B, up 82% to 91% from last year 08/24/20 Dada Nexus reports Q2 EPS (11c), one estimate (18c) COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) 03 Dec 03 Dec 01 Dec 02 Dec 02 Dec 15 Oct 17 Sep 11 Sep 14 Aug 06 Aug 01 Jul 03 Jun 05 Jun 05 Jun 19 May 14 Feb 12 Feb ZM TSLA MRNA ZM Zoom Video $479.28 / +7.98 (+1.69%) 11/13/20 NYC mayor warns parents to plan for school shutdown, Bloomberg reports 11/10/20 Microsoft wants to demolish video-conferencing competition, BI reports 10/14/20 Zoom's Yuan says won't develop chat service to rival Slack, Bloomberg reports 09/26/20 Western Digital could have plenty of upside, Barron's says TSLA Tesla $567.00 / -18.77 (-3.20%) 11/30/20 Tesla receives approval from China for Shanghai-made Model Y, Reuters reports 11/29/20 Tesla delayed Semi truck testing Musk's ability to scale up, WSJ says 11/27/20 About 115,000 Tesla vehicles probed for suspension issues by NHTSA, Reuters says 11/25/20 Tesla issues recalls covering 9,500 U.S. cars, Reuters reports MRNA Moderna $152.93 / +25.97 (+20.46%) 11/24/20 Ford purchases freezers to store Covid vaccines, Reuters reports 11/18/20 FDA may host panel to discuss COVID-19 vaccines in December, CNBC says 11/16/20 EU seeks COVID vaccine pact with Moderna at under $25 per dose, Reuters says 11/11/20 Fauci predicts positive vaccine data coming 'soon' from Moderna, FT reports ZM TSLA OSH NTLA NOVA NCNA MRNA FOUR DADA ARRY ZM Zoom Video $479.28 / +7.98 (+1.69%) 11/30/20 Fly Intel: What to watch in Zoom Video earnings report 11/11/20 #SocialStocks: Zoom seeks to maintain tailwind despite COVID-19 vaccine news 11/09/20 Pfizer, BioNTech lift market as COVID vaccine shows effectiveness 11/09/20 Fly Intel: Pre-market Movers TSLA Tesla $567.00 / -18.77 (-3.20%) 11/18/20 Fly Intel: Wall Street's top stories for Wednesday 11/18/20 Fly Intel: Wall Street's top stories at midday 11/18/20 Tesla, Boeing upgrades among today's top calls on Wall Street 11/18/20 Fly Intel: Pre-market Movers OSH Oak Street Health $47.17 / +0.17 (+0.36%) 08/09/20 Opening Day: Quicken Loans parent raises only $1.8B in IPO NTLA Intellia Therapeutics $39.28 / -0.07 (-0.18%) 06/01/20 Fly Intel: After-Hours Movers NOVA Sunnova Energy $40.52 / -4.43 (-9.86%) 10/28/20 Fly Intel: After-Hours Movers 10/12/20 Fly Insider: Element Solutions, Sunrun among week's notable insider trades NCNA NuCana $4.49 / -0.01 (-0.22%) 11/19/20 Fly Intel: After-Hours Movers 09/17/20 Fly Intel: Pre-market Movers 09/16/20 Fly Intel: After-Hours Movers 07/23/20 Fly Intel: After-Hours Movers MRNA Moderna $152.93 / +25.97 (+20.46%) 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/30/20 Fly Intel: Pre-market Movers 11/27/20 Fly Intel: Wall Street's top stories for Friday FOUR Shift4 Payments $61.23 / -0.43 (-0.70%) 11/05/20 Fly Intel: Pre-market Movers DADA Dada Nexus $57.97 / +2.3899 (+4.30%) 06/07/20 Opening Day: ZoomInfo soars in first tech IPO of COVID era 06/05/20 Fly Intel: Wall Street's top stories for Friday 06/05/20 Fly Intel: Wall Street's top stories at midday ARRY Array Technologies $45.29 / -1.86 (-3.94%) 10/18/20 Opening Day: Array jumps after $1.05B IPO 10/11/20 Opening Day: iHuman makes trading debut amid U.S.-China tensions 11/30/20 24th Annual Technology Virtual Conference 12/01/20 2020 Wells Fargo TMT Virtual Summit 12/01/20 3rd Annual HealthCONx Virtual Conference 12/02/20 32nd Annual Virtual Healthcare Conference 12/11/20 Semi-Annual Silicon Valley Virtual Tour 11/30/20 Zoom Video - ZM 11/30/20 Noah Holdings - NOAH 12/01/20 Sunnova Energy 12/17/20 Oak Street Health ZM TSLA OSH NOVA NOAH MRNA FOUR ARRY ZM Zoom Video $479.28 / +7.98 (+1.69%) 11/30/20 Zoom Video Communications options imply 20.2% move in share price post-earnings 10/13/20 Zoom Video Communications call volume above normal and directionally bullish 10/05/20 Unusual call flow in option market yesterday TSLA Tesla $567.00 / -18.77 (-3.20%) 11/30/20 Notable open interest changes for November 30th 11/27/20 Notable open interest changes for November 27th 11/25/20 Notable open interest changes for November 25th 11/24/20 Notable open interest changes for November 24th OSH Oak Street Health $47.17 / +0.17 (+0.36%) 10/05/20 Eight new option listings and two option delistings on October 5th NOVA Sunnova Energy $40.52 / -4.43 (-9.86%) 10/28/20 Sunnova Energy options imply 20.0% move in share price post-earnings 08/26/20 Eight new option listings on August 26th NOAH Noah Holdings $29.53 / -4.12 (-12.24%) 11/30/20 Noah Holdings options imply 10.3% move in share price post-earnings 08/24/20 Noah Holdings options imply 3.1% move in share price post-earnings MRNA Moderna $152.93 / +25.97 (+20.46%) 11/27/20 Moderna call buyer realizes 22% same-day gains 11/25/20 Moderna call volume above normal and directionally bullish 11/13/20 Unusually active option classes on open November 13th 11/12/20 Unusually active option classes on open November 12th FOUR Shift4 Payments $61.23 / -0.43 (-0.70%) 06/17/20 Five new option listings on June 17th ARRY Array Technologies $45.29 / -1.86 (-3.94%) 11/02/20 Nine new option listings and four option delistings on November 2nd
Syndicate	Cogent Biosciences announces $60M common stock offering » 16:03 11/30/20 11/30 16:03 11/30/20 16:03 COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) Cogent Biosciences… Cogent Biosciences announced that it has commenced an underwritten public offering of $60M of shares of its common stock. Cogent Biosciences intends to use the net proceeds from the offering for development, regulatory and commercial preparation activities relating to PLX9486 and other product candidates, as well as for working capital and general corporate purposes. Jefferies and Piper Sandler & Co. are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, and Ladenburg Thalmann are also acting as co-managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Events COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/30/20 Cogent Biosciences appoints Brad Barnett as Chief Technology Officer 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg COGT Cogent Biosciences $10.02 / +0.23 (+2.35%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) 12/02/20 32nd Annual Virtual Healthcare Conference
Hot Stocks	Cogent Biosciences appoints Brad Barnett as Chief Technology Officer » 07:01 11/30/20 11/30 07:01 11/30/20 07:01 COGT Cogent Biosciences $9.60 / +0.15 (+1.59%) Cogent Biosciences… Cogent Biosciences announced the appointment of Brad Barnett as Chief Technology Officer. In his new role, Barnett will be responsible for all aspects of chemistry, manufacturing and controls,, technical development, supply chain operations, and alliance management. "We are excited to welcome Brad to the growing Cogent Biosciences team. Brad's extensive experience leading the manufacturing and supply chain organization at Array BioPharma will prove invaluable as we expand PLX9486 into clinical trials for systemic mastocytosis and gastrointestinal stromal tumor patients," said Andrew Robbins, President & CEO of Cogent Biosciences. "I had the pleasure of working with Brad at Array, and I am excited to reconnect as we execute on our development plans for PLX9486. Additionally, Brad will be a great asset to our team as we look to the future of the company including building a portfolio of new, selective, and potent precision medicines around our lead asset PLX9486." ShowHide Related Items >><< Company News Street Research Earnings Events COGT Cogent Biosciences $9.60 / +0.15 (+1.59%) 11/18/20 Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson COGT Cogent Biosciences $9.60 / +0.15 (+1.59%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg COGT Cogent Biosciences $9.60 / +0.15 (+1.59%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) 12/02/20 32nd Annual Virtual Healthcare Conference
Hot Stocks	Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST » 09:04 11/18/20 11/18 09:04 11/18/20 09:04 COGT Cogent Biosciences $9.70 / -0.4 (-3.96%) Cogent Biosciences… Cogent Biosciences announced the final results from its PLX9486 + sunitinib Phase 1/2 study in patients with advanced gastrointestinal stromal tumors, or GIST. PLX9486 is a selective tyrosine kinase inhibitor designed to potently inhibit KIT exon 17 mutations, including D816V. Most patients with imatinib-resistant GIST have both primary and secondary KIT mutations. These data suggest that treatment with a combination of PLX9486 and sunitinib may provide substantial clinical benefit over treatment with type I or type II inhibitors alone. A majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavily pre-treated GIST population; 27% of patients remain on therapy out 27-34 months. The combination showed no dose limiting toxicities and no maximum tolerated dose was reached. Single agent ctDNA analysis supports PLX9486 specificity and demonstrates clinical activity against KIT exon 17 mutation. A Phase 3 GIST trial initiation is planned for 2H 2021. ShowHide Related Items >><< Company News Street Research Earnings Events COGT Cogent Biosciences $9.70 / -0.4 (-3.96%) 10/26/20 Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson COGT Cogent Biosciences $9.70 / -0.4 (-3.96%) 11/10/20 Wedbush Cogent Biosciences price target raised to $24 from $6 at Wedbush 10/14/20 Ladenburg Ladenburg starts Cogent Biosciences with Buy, $4 price target 10/14/20 Ladenburg Cogent Biosciences initiated with a Buy at Ladenburg COGT Cogent Biosciences $9.70 / -0.4 (-3.96%) 11/09/20 Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c) 12/02/20 32nd Annual Virtual Healthcare Conference

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial